Effectiveness and safety of intermittent fasting on blood pressure in adults with overweight or obesity: a systematic review
Guo Y, Lu L, Chen L, Wang Y, Zhao F, Jiang Y
International journal of obesity (2005) · 3 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-07-01 · Int J Obes (Lond) · vol. 49 · número 7 · págs. 1240–1251
- Editorial
- Springer Nature
- Citado
- 4 citas · más que el 65% de estudios similares · 0.8× el promedio de su campo
- Referencias
- 67 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Blood Pressure and Hypertension Studies · Sodium Intake and Health
- Palabras clave
- intermittent fasting, blood pressure, hypertension, obesity, overweight, antihypertensive effect, insulin resistance, triglycerides, anthropometric measures, adverse effects, vomiting, irritability, cardiometabolic risk markers, older adults, prehypertension, weight loss dieting, Chinese adults, sex differences, age differences, baseline blood pressure
- MeSH
- humans, hypertension, obesity, fasting, blood pressure, adult, middle aged, female, male, overweight, intermittent fasting
6 autores
- Yaxin Guo🇨🇳Xiyuan Hospital; China Academy of Chinese Medical Sciences; Shanxi University of Traditional Chinese Medicine
- Lijie Lu🇨🇳Xiyuan Hospital; China Academy of Chinese Medical Sciences; Shanxi University of Traditional Chinese Medicine
- Luying Chen🇨🇳Xiyuan Hospital; China Academy of Chinese Medical Sciences
- Yaojian Wang🇨🇳Xiyuan Hospital; China Academy of Chinese Medical Sciences
- Fangfang Zhao🇨🇳 · autor de correspondenciaXiyuan Hospital; China Academy of Chinese Medical Sciences
- Yuerong Jiang🇨🇳 · autor de correspondenciaXiyuan Hospital; China Academy of Chinese Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Previous intermittent fasting (IF) studies have reported inconsistent findings regarding its antihypertensive effects and safety.
Objective
This study aimed to assess the effects and safety of IF on blood pressure (BP), anthropometrics, and cardiometabolic risk markers in individuals with overweight or obesity compared to a no-intervention control group.
Methods
Relevant studies were retrieved from multiple databases, including CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, the Cochrane Library, and Web of Science, up to April 30, 2024. A meta-analysis was performed using Stata version 18.0 and RevMan 5.4, calculating mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI) via the Knapp-Hartung modified random-effects model. Publication bias was evaluated using a contour-enhanced funnel plot and Egger's test.
Results
Fifteen studies (n = 929) were included. IF significantly reduced systolic blood pressure (SBP) (MD = -4.43 mmHg, 95% CI: -5.83 to -3.03, p < 0.001) and diastolic blood pressure (DBP) (MD = -2.00 mmHg, 95% CI: -3.23 to -0.78, p < 0.001) compared to control. IF also improved anthropometric measures, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and Triglycerides (TG). Seven studies reported minor adverse effects. Although the IF group showed a higher risk of vomiting (RR = 1.11, 95% CI: 1.04-1.19, p = 0.01) and irritability (RR = 1.22, 95% CI: 1.13-1.31, p < 0.001) compared to the control group, these reactions were predominantly observed during the initial phase of the intervention and were self-resolving.
Conclusions
IF significantly lowered SBP and DBP in individuals with overweight or obesity, particularly in high-risk subgroups (obesity, age ≥45 years, and prehypertension/hypertension), with a favorable safety profile. Due to heterogeneity, future trials should standardize IF regimens and target these subgroups to confirm generalizability.
Clinical trial registration
The review protocol has been registered on PROSPERO (CRD42024540777).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.